PFE catalyst calendar

PFIZER INC

Upcoming catalysts
17
Cash runway
Cash generating
Cash & investments
$976M
Phase 3 programs
18

PFIZER INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 3, 2026, a projected date rather than a confirmed one. There are 17 upcoming events on record.

PFIZER INC generates cash from operations, so a burn-based runway figure does not apply.

Across 397 concluded trials, 82% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 3, 2026 est. Next quarterly earnings (projected) Earnings —
January 18, 2027 Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. Trial Milestone Phase 3
February 23, 2027 A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function Trial Milestone Phase 1
March 30, 2027 A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma Trial Milestone Phase 1
April 25, 2027 A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH) Trial Milestone Phase 2
June 16, 2027 A Study of Sigvotatug Vedotin in Advanced Solid Tumors Trial Milestone Phase 1
October 25, 2027 A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer Trial Milestone Phase 1/Phase 2
December 2, 2027 Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents Trial Milestone Phase 3
January 5, 2028 A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Trial Milestone Phase 1
March 21, 2028 Crizotinib Continuation Clinical Study Trial Milestone Phase 4
July 14, 2028 Phase 1 Study of PF-08046033 in Advanced Solid Tumors Trial Milestone Phase 1
July 29, 2028 Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC Trial Milestone Phase 2
October 21, 2028 A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine Trial Milestone Phase 3
June 1, 2029 Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer Trial Milestone Phase 3
July 31, 2030 Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine Trial Milestone Phase 3
July 29, 2031 A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies Trial Milestone Phase 3
February 22, 2032 Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) Trial Milestone Phase 4

Track PFE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open PFE in the tracker

Recent history

DateEventTypePhase
August 21, 2026 A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults Trial Milestone Phase 1
August 4, 2026 Quarterly results filed (8-K) Earnings —
July 16, 2026 A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults. Trial Milestone Phase 1
June 18, 2026 8-K filed: Leadership change Corporate —
June 18, 2026 8-K filed: Reg FD disclosure Filing —
May 12, 2026 A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults Trial Milestone Phase 1/Phase 2
May 5, 2026 Quarterly results filed (8-K) Earnings —
April 21, 2026 A Study of MET233 in Individuals With Obesity or Overweight Trial Milestone Phase 1
April 15, 2026 A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults Trial Milestone Phase 1
April 9, 2026 A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. Trial Milestone Phase 1/Phase 2
March 20, 2026 A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies Trial Milestone Phase 1
February 3, 2026 Quarterly results filed (8-K) Earnings —
January 28, 2026 A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults Trial Milestone Phase 1
January 7, 2026 An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) Trial Milestone Phase 3
January 6, 2026 A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults. Trial Milestone Phase 1
December 18, 2025 A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults. Trial Milestone Phase 1
December 17, 2025 A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144 Trial Milestone Phase 1
December 16, 2025 8-K filed: Reg FD disclosure Filing —
December 10, 2025 A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers Trial Milestone Phase 1
November 21, 2025 8-K filed: Other event Filing —
November 21, 2025 A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults Trial Milestone Phase 1
November 13, 2025 8-K filed: Other event Filing —
November 4, 2025 Quarterly results filed (8-K) Earnings —
October 24, 2025 A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults Trial Milestone Phase 1
September 20, 2025 A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan Trial Milestone Phase 3
August 5, 2025 Quarterly results filed (8-K) Earnings —
July 24, 2025 A Study Comparing Subcutaneous Injection of Sayana Press In the Upper Arm Versus Anterior Thigh and Abdomen Trial Milestone Phase 1
May 19, 2025 8-K filed: Other event Filing —
April 29, 2025 Quarterly results filed (8-K) Earnings —
December 24, 2024 A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.